Methylene Blue 15mg

Oral capsule: Swallow intact with a full glass of water. May be taken with or without food; taking with food may reduce GI discomfort. Patients should be informed that methylene blue imparts a blue-green discoloration to urine and stool — this is expected and not harmful. Consistent daily timing is preferred for stable plasma levels. Do not open or crush the capsule.

Dosing is prescriber-determined and highly individualized. Low-dose investigational protocols vary widely in the literature.

• Low-dose range (cognitive/neuroprotective applications): Clinical investigation has used single daily doses in the low-milligram range; 15 mg represents a commonly prescribed starting or maintenance dose in prescriber-supervised protocols.
• Higher doses (>2 mg/kg IV) are used for FDA-approved methemoglobinemia treatment — an entirely different clinical application and route.
• The prescriber determines the indication, dose, frequency, and duration. Off-label cognitive or metabolic use lacks formal FDA-approved dosing standards.

• Methylene Blue: Acts as a lipophilic, auto-oxidizing redox cycler. At low doses, it accepts electrons from NADH at Complex I and donates them directly to cytochrome c, effectively bypassing Complexes I–III of the mitochondrial electron transport chain. This enhances mitochondrial oxygen consumption and ATP production while reducing superoxide generation and oxidative stress — the basis of its proposed neuroprotective and memory-supporting properties. Additionally, methylene blue reversibly inhibits monoamine oxidase A (MAO-A), increases serotonin and dopamine availability, and inhibits nitric oxide synthase (NOS) and soluble guanylate cyclase, reducing excess cGMP-mediated vasodilation. In methemoglobinemia (its sole FDA-approved indication), it is reduced by NADPH-methemoglobin reductase to leucomethylene blue, which reduces ferric hemoglobin (Fe³⁺) back to functional ferrous (Fe²⁺) form.

FDA-approved use: Treatment of acquired methemoglobinemia (IV formulation). Investigated off-label applications — for which evidence is preliminary and largely preclinical — include neuroprotective and cognitive support strategies (Alzheimer's disease, traumatic brain injury, post-viral cognitive symptoms), ifosfamide-induced encephalopathy (off-label, IV), and vasoplegic shock (IV). This 15 mg oral compounded formulation is prescribed for off-label investigational use under prescriber direction.

Prescriber monitoring:

• Baseline G6PD (glucose-6-phosphate dehydrogenase) status — G6PD-deficient patients are at risk for hemolytic anemia
• Monitor for serotonin syndrome, particularly in patients on serotonergic medications (SSRIs, SNRIs, MAOIs, triptans)
• Assess renal function — methylene blue is renally excreted
• Use with extreme caution in patients taking apomorphine (sublingual) — potentially life-threatening hypotension reported

Contraindications:

• G6PD deficiency — risk of hemolytic anemia and paradoxical methemoglobin worsening
• Hypersensitivity to methylene blue or thiazine dyes
• Concurrent use with serotonergic drugs (high risk of serotonin syndrome)
• Concurrent use with apomorphine — documented severe hypotension/syncope risk

Warnings & Precautions:

• Serotonin syndrome: methylene blue inhibits MAO-A; combining with SSRIs, SNRIs, clomipramine, or other serotonergic agents can cause potentially fatal serotonin toxicity — prescribers must carefully review all serotonergic medications
• Blue-green discoloration of urine and stool is expected and harmless at therapeutic doses
• At doses above 7 mg/kg, methylene blue can paradoxically cause methemoglobinemia
• Photosensitivity — advise adequate sun protection

Drug Interactions:

• SSRIs, SNRIs, MAOIs, triptans: serotonin syndrome (contraindicated or extreme caution)
• Apomorphine: life-threatening hypotension and syncope
• CYP2C19 substrates: potential inhibition

Common Side Effects: Blue-green urine/stool, nausea, vomiting, abdominal pain, headache, dizziness, anxiety, confusion at higher doses, skin discoloration with prolonged use.

Store compounded methylene blue capsules at room temperature (15–25°C), protected from light and moisture. Methylene blue is photosensitive; keep in an opaque or light-resistant container. Do not freeze. Observe the beyond-use date assigned by Genesis Compounding and discard expired product appropriately.

Why does my urine turn blue or green?

Methylene blue and its metabolites are excreted renally, imparting a characteristic blue-green color to urine (and sometimes stool). This is expected, harmless at therapeutic doses, and resolves after the medication is stopped.

Is methylene blue FDA-approved?

Methylene blue is FDA-approved only for intravenous treatment of acquired methemoglobinemia. This oral 15 mg compounded preparation is for off-label investigational use as directed by the prescriber and has not been evaluated by the FDA for safety or efficacy as a compounded product.

Can I take this if I am on an antidepressant?

This is a critical safety question. Methylene blue inhibits MAO-A and can cause severe, potentially fatal serotonin syndrome when combined with SSRIs, SNRIs, or other serotonergic medications. Prescribers must evaluate all concurrent medications before ordering methylene blue.

What is the evidence for cognitive benefits?

Preclinical and small human studies suggest that low-dose methylene blue enhances mitochondrial efficiency and may support memory and brain energy metabolism. However, large, controlled clinical trials establishing efficacy for cognitive enhancement are lacking, and this use is not FDA-approved.

How should I store this medication?

Keep at room temperature in the original container away from light and moisture. Observe the beyond-use date on the label and do not use after that date.